RA Latex Test: Assesses rheumatoid factor levels to evaluate for rheumatoid arthritis.
IU/mL
Enter RF Level
Enter the rheumatoid factor level in IU/mL to interpret the RA Latex test result.
Guidelines & Evidence
Verified
Last Review: 2026-07-17
When to Use
When to Use
Detection of rheumatoid factor (RF) as part of the diagnostic workup for suspected RA
Quantitative measurement of RF isotypes (IgM, IgA, IgG) for disease classification
Supporting the ACR/EULAR 2010 classification criteria for RA
Serial monitoring of RF titres in established RA (limited utility)
Evaluating patients with undifferentiated inflammatory arthritis
Patient Population
Adults presenting with inflammatory arthritis or suspected RA. The latex agglutination test is a qualitative and semi-quantitative method for detecting RF, predominantly IgM antibodies directed against the Fc portion of human IgG.
Contraindications
Not diagnostic for RA in isolation; RF can be negative in RA and positive in healthy individuals
RF positivity is not specific to RA and occurs in many other conditions
Not useful as a screening test in the general population due to low positive predictive value
The latex test is less sensitive than nephelometric methods for low-level RF detection
How it Works
Principle
The RA latex test is based on the agglutination of latex particles coated with human IgG. When a patient serum containing rheumatoid factor (anti-IgG antibodies, primarily IgM) is mixed with the coated latex particles, the RF binds to the IgG on the particles, causing visible agglutination (clumping). The degree of agglutination is proportional to the RF concentration.
Method
01
Patient serum is serially diluted (typically 1:20, 1:40, 1:80, 1:160, etc.)
02
Each dilution is mixed with latex particles coated with human IgG
03
The mixture is gently rotated for 2–3 minutes
04
Agglutination is assessed visually or by turbidimetry
05
The highest dilution showing visible agglutination is reported as the titre
06
Results are reported qualitatively (positive/negative) or semi-quantitatively (titre)
Interpretation
| Result | Titre | Clinical Implication |
|---|---|---|
| Negative | < 1:20 | RF not detected; does not rule out RA (especially early or seronegative) |
| Low-positive | 1:20 – 1:80 | May be seen in RA, but also in ageing, infections, and other autoimmune diseases |
| Moderate-positive | 1:80 – 1:320 | Suggests RA, especially if symptomatic; high-positive confers worse prognosis |
| High-positive | > 1:320 | Strongly associated with RA; associated with extra-articular disease and erosions |
Clinical Pearls
Clinical Application
The RA latex test detects RF, which has a sensitivity of approximately 70–80% and specificity of approximately 80–90% for RA. Anti-CCP (ACPA) has superior specificity (~95%) and comparable sensitivity and has largely replaced RF as the preferred serologic marker when only one test can be performed. When both RF and ACPA are positive, the specificity for RA exceeds 95%. RF is more useful as part of a diagnostic panel than as a standalone test and is a required element of the ACR/EULAR 2010 criteria.
Causes of False Positive RF
Other autoimmune diseases: Sjögren syndrome, SLE, mixed connective tissue disease, cryoglobulinaemia
Chronic infections: hepatitis C, hepatitis B, tuberculosis, subacute bacterial endocarditis
Malignancy: particularly lymphoproliferative disorders and multiple myeloma
Chronic lung disease: sarcoidosis, interstitial pulmonary fibrosis
Ageing: up to 10–15% of healthy elderly individuals (> 70 years) have low-positive RF
Paraproteinaemias and hypergammaglobulinaemia
Pitfalls to Avoid
Never use RF alone to diagnose or exclude RA; always interpret in clinical context
A negative RF does not rule out RA (15–30% of RA patients are seronegative)
Test timing matters: RF seroconversion can occur months after symptom onset
The latex test is semi-quantitative; nephelometry provides more precise quantification
Serial RF titres do not correlate well with disease activity and should not be used to monitor treatment
Next Steps
Seropositive (Positive RF)
01
Use in conjunction with ACPA, joint examination, and imaging to assess likelihood of RA
02
If ACR/EULAR 2010 criteria met, initiate DMARD therapy (MTX first-line)
03
Seropositive RA is associated with more aggressive disease; consider early combination therapy
04
Monitor for extra-articular manifestations: rheumatoid nodules, vasculitis, interstitial lung disease
05
Screen for hepatitis C if RF is positive, especially if immunosuppression is planned
Seronegative (Negative RF)
01
Test for ACPA (anti-CCP), which may be positive when RF is negative
02
If high clinical suspicion and negative serology, repeat testing in 3–6 months
03
Consider other diagnoses: psoriatic arthritis, reactive arthritis, gout, CPPD
04
Seronegative RA may still require DMARD therapy if clinical features are convincing
05
MSK ultrasound or MRI can help detect subclinical synovitis
The Evidence
Key Evidence
RF has sensitivity ~70% and specificity ~85% for RA in meta-analyses
High-titre RF is associated with more severe disease, radiographic progression, and extra-articular manifestations
The combination of RF + ACPA positivity increases specificity for RA to > 95%
RF is included in the ACR/EULAR 2010 classification criteria and is a core serologic test in RA evaluation
Primary Reference
Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis.
Nishimura K et al. • Annals of Internal Medicine. 2007;146(11):797-808
2010 Rheumatoid arthritis classification criteria: an ACR/EULAR collaborative initiative.
Aletaha D et al. • Arthritis and Rheumatism. 2010;62(9):2569-81
Origins & History
Development
The RA latex test was developed in the 1950s as a simpler alternative to the Rose-Waaler sheep cell agglutination test, which was the original method for detecting rheumatoid factor. The latex fixation test, introduced by Singer and Plotz in 1956, uses polystyrene latex particles coated with human gamma globulin. The test became widely adopted due to its simplicity, speed, and low cost, and remains in common use worldwide as a screening tool for RF.
Last Comprehensive Review: 2026-07-17